Introduction
Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the United States. In 1997 approximately 26 700 women will be diagnosed with ovarian cancer, while 14 800 women will die due to this disease (Parker et al., 1996) . Ovarian cancer has a high mortality rate since the vast majority of women are diagnosed at late stages. Recent studies have focused on characterizing the genetic alterations which are involved in the process of ovarian carcinogenesis. Critical to this examination is the role that tumor suppressor genes play in the development of ovarian cancer. Cytogenetic and molecular studies have attempted to pinpoint the sites of alteration leading to the development of this disease by noting alterations at chromosome 3p (Tanaka et al., 1989) , 5q (Weitzel et al., 1994) , 6q (Rodabaugh et al., 1995b; Lee et al., 1990; Foulkes et al., 1993b; Sato et al., 1991) , 9p (Rodabaugh et al., 1995a) , 11 (Eccles et al., 1992a; Davis et al., 1996; Lee et al., 1990; Gallion et al., 1990 Gallion et al., , 1992 , 13 (Yang-Feng et al., 1992 Sato et al., 1991; Gallion et al., 1992; Dodson et al., 1993) , 17 (Wertheim et al., 1994; Foulkes et al., 1993a; Eccles et al., 1992b; Tangir et al., 1996; Pieretti et al., 1995; Lee et al., 1990; Cliby et al., 1993; Yang-Feng et al., 1993; Gallion et al., 1992; Dodson et al., 1993) , 19 (Sato et al., 1991) , 22 (Bryan et al., 1996) , and X (Yang-Feng et al., 1992; Cheng et al., 1996) .
Chromosome 7 has been a focus of attention as a site harboring a tumor suppressor gene. Ogata et al. performed studies using the nontumorigenic immortalized human ®broblast cell lines KMST-6(KMST) and SUSM-1(SUSM) which have LOH in the segment 7q31-q32 (Ogata et al., 1993) . They found that the introduction of intact chromosome 7 into KMST-6 and SUSM-1 by means of microcell fusion resulted in the cessation of division, giving rise to cells which appear to be in senescence. In a subsequent microcell-mediated chromosome transfer experiment, Zenklusen et al. (1994b) introduced chromosome 7 into the murine squamous cell carcinoma cell line CH72 and injected them into nude mice to assay for tumorigenicity. Five of the seven hybrid clones that contained an intact chromosome 7 showed a 2 ± 3-fold delay in the expression of the malignant phenotype of CH72 cells. One of the hybrid clones that failed to show the delayed tumorigenicity was noted to have a deletion of chromosome 7q31.1 ± 31.3 segment suggesting that a tumor suppressor gene may be located on the long arm of chromosome 7.
While cytogenetic studies have noted deletions of chromosome 7q in various tumor types (Atkin et al., 1993) , recent molecular genetic studies have sought to determine the smallest region on chromosome 7 involved in genetic alterations. Using microsatellite repeat ampli®cation analysis, frequent allelic loss on chromosome 7q has been shown in a number of tumors including breast carcinoma (Zenklusen et al., 1994a) , head-and-neck carcinoma (Zenklusen et al., 1995a) , prostate carcinoma (Zenklusen et al., 1994c; Takahashi et al., 1995) , colon carcinoma (Zenklusen et al., 1995a) , and malignant myeloid disorder (Abrahamson et al., 1993) . These studies have further provided evidence that a tumor suppressor gene exists at 7q31.1.
In epithelial ovarian cancers, early studies by Sato et al. (1991) and Cliby et al. (1993) showed only 13 ± 21% LOH on chromosome 7 in their tumor samples. Zenklusen et al. (1995b) examined LOH in chromosome 7q in 26 primary ovarian carcinomas using 14 (C-A)n microsatellite repeats. All 26 cases exhibited LOH at one or more loci on 7q with 73% LOH detected in D7S522 at 7q31.1. With percentage of LOH normally distributed around the microsatellite D7S522, a smallest common deleted region of 1cM at 7q31.1 was proposed as the region harboring a tumor suppressor gene relevant to the development of ovarian cancer. Recently, Kerr et al. (1996) performed LOH analysis in the region of 7q21-q31 and found two critical regions, a proximal region between PLANH1 and D7S471 and a distal region around D7S522, which may be important in subsets of ovarian epithelial tumors.
The present investigation reports the construction of a detailed deletion map of chromosome 7q31 from 54 invasive epithelial ovarian carcinomas using 13 microsatellite markers in an eort to further narrow the common deleted region. We also sought to investigate whether LOH in this region is involved in the development of borderline ovarian tumors.
Results

LOH on chromosome 7q31
A set of 13 microsatellite markers spanning the region from 7q31 to 7q32 ( Figure 1 ) were used to perform LOH study on 54 ovarian carcinomas and 16 borderline ovarian tumors with diering stages and grades. All cases showed constitutional heterozygosity for several of the microsatellite loci tested. Thirty-two of the 54 (59%) informative patients with invasive epithelial ovarian cancer exhibited LOH aecting at least one locus. Figure 2 shows an example of autoradiographs depicting LOH and the normal control in the adjacent lane.
The percentage of tumors with allelic loss at each locus is shown in Figure 1 . The loci that showed the highest percentage LOH were D7S643 (20 of 40 informative cases, 50%) and GATA44F09 (18 of 42 informative cases, 43%). All other loci showed a much lower percentage of LOH rate. Three of the 54 cases (Cases 336, 403, 412) showed allelic loss at almost all the loci suggesting that these samples had LOH in the whole 7q31 region. Therefore, these cases were not informative for the localization of the smallest region of allelic loss where the candidate tumor suppressor gene may reside. The remaining 29 cases showed restricted LOH patterns which allowed us to de®ne two regions of common loss. One distinct region, approximately 1300 kilobases, is located between the markers GATA44F09 and D7S643. The identi®cation of this region was based on the study of cases ES-3, B17, B19, B21, 321, 357, 377, 402, 428, and 425 (Figure 3) . A second region of common loss was observed proximally between the markers D7S2502 and D7S633. This region is suggested by cases 357, 377, 383, 386, 402, 425, 443, 489, 516, 527 and 528. Sixteen borderline ovarian tumors were analysed using eight microsatellite markers from the 7q31 region including D7S643 and GATA44F09. The borderline ovarian tumors did not show LOH at seven of eight loci. At the locus GATA44F09, only one tumor (case 514) exhibited LOH. (Table 1) .
Discussion
In this study of 54 ovarian carcinomas utilizing 13 loci spanning 7q31 to 7q32, we have performed detailed deletion mapping in order to identify areas where a tumor suppressor gene may be located. A 1300 kilobase region¯anked by the loci GATA44F09 and D7S643 is one region of chromosome 7q31.3 which may be a candidate locus for the putative tumor suppressor gene signi®cant for invasive epithelial carcinomas.
A second tumor suppressor gene region loci may also be present in the region¯anked by the markers D7S2502 and D7S633. A tumor suppressor gene for epithelial tumors has been postulated in this region based on the high rate of allelic loss found in prostate, breast, colon, and ovary carcinomas (Zenklusen et al., 1996) . We only observed a 29% LOH (eight of 28 informative cases) rate for D7S522. This was similar to the results of Kerr et al. (1996) (34%) but diers from the results of Zenklusen et al. (1995b) who reported 73% LOH detection (14 of 19 informative cases) in D7S522. The discrepancy between our results and those of Zenklusen et al. (1995b) may be due to the total number of informative cases and cases of dierent stages and grades that were examined. Both studies had a similar number of grade 1 and 2 informative cases, but our study had a total of 21 grade 3 informative cases as compared to seven in the Zenklusen study.
We observed that allelic loss at 7q31.3 was equally likely to occur in all grades and stages of invasive ovarian carcinomas. This suggests that inactivation of a tumor suppressor gene in this region is an early event in ovarian tumorigenesis. Furthermore, our study discloses a de®nite dierence between borderline and invasive ovarian tumors on chromosome 7q31. LOH was observed in at least one locus in 59% of the invasive epithelial carcinomas and 7% of the borderline tumors (P50.005) screened. It would, therefore, appear that LOH at chromosome 7q31 may not be involved in the development and progression of borderline ovarian tumors. This is additional evidence that borderline and invasive tumors are separate entities.
In conclusion, we have provided further evidence for the presence of important tumor suppressor genes located on chromosome 7q31.3 by identifying two critical regions. The ®rst region,¯anked by the markers D7S2502 and D7S633, has been suggested to harbor a tumor suppressor gene relevant to a wide variety of epithelial tumors. A second region of allelic loss which has not been identi®ed previously as a candidate tumor suppressor gene locus is 1300 kilobases and¯anked by GATA44F09 and D7S643. Candidate genes are presently being investigated by using a positional cloning approach.
Materials and methods
Specimen collection and DNA extraction
Surgical specimens of human ovarian tissue were obtained from 54 patients under a protocol approved by the Human Subjects Committee of the Brigham and Women's Hospital. Archival materials consisted of 13 sets of paran blocks. The corresponding control tissues consisted of segments of normal fallopian tube, uninvolved round ligament, or peripheral blood. All histopathologic diagnoses of ovarian epithelial tumors were con®rmed by a gynecologic pathologist. Invasive carcinomas were graded, and all tumors were surgically staged according to FIGO criteria (International Federation of Gynecology and Obstetrics, 1987) . The invasive tumors consisted of 38 serous adenocarcinomas, four mucinous cystadenocarcinomas, ®ve endometrioid adenocarcinomas, four mixed epithelial carcinomas, two clear cell carcinomas, and one undierentiated carcinoma of the ovary. Of the borderline tumors, 10 were serous, and the remaining six were mucinous tumors.
DNA extraction
DNA was extracted from fresh tissue of 16 borderline tumors and 41 invasive cancers. In 13 cases (all invasive epithelial), DNA was extracted from archival materials which had been previously ®xed in formalin and embedded in paran. Blocks containing predominantly tumor tissue were marked and selectively trimmed for tumor concentration prior to DNA extraction. Paran sections were deparanized with xylene followed by absolute ethanol. All tissues, both deparanized and fresh, were incubated in digestion buer (5 M NaCl, 1 M Tris-Cl, 0.5 M EDTA, 10% SDS and 0.1 mg ml 71 proteinase K) overnight at 508C, followed by a series of phenol: chloroform extractions interrupted by an RNase digestion. The DNA was ®nally precipitated in cold ethanol with sodium acetate and resuspended in Tris-EDTA buer, pH 7.5.
PCR and LOH studies
LOH was performed by PCR ampli®cation of tandem repeats located at thirteen loci on chromosome 7q31. The map position and genetic distance between primers are based on the chromosome 7-speci®c YAC library constructed by our group and the CEPH collection (Kunz et al., 1994; Scherer et al., 1992) . A revised order of the chromosome 7 markers have been reported recently (Lin et al., 1996) . The dierent loci and their map positions are summarized in Figure 1 . The forward primer of each set was end labeled with gamma 32 P-ATP (ICN, Irvine, CA) and polynucleotide kinase (Boehringer Mannheim, Indianapolis, IN). The reaction mix was then diluted into a ®nal volume of 320.5 ml of primer-PCR mixture containing 40 ml 106PCR Buer (0.1 M Tris-HCl, 0.5 M KCl, pH 8.3), 20 ± 50 mM MgCl 2 , 20 ml 1.25 mM dNTP, 2.0 ml (10 units) of Taq Polymerase (Perkins-Elmer Cetus, Norwalk, CT), and 1 ml of each primer. Four ml of this PCR mixture was mixed with each DNA sample. Ampli®cation was carried out using 50 ng of genomic DNA using 35 cycles of PCR for 30 s and extension at 728C for 30 s. PCR products were diluted in 45 ml of loading buer containing 95% formamide, 20 mM EDTA, 0.05% bromphenol blue, and 0.05% xylene cyanol FF (Sigma, St Louis, MO). Three ml of this mixture was then loaded onto a 6% acrylamide denaturing gel and electrophoresed at a constant 1700 volts. The gel was transferred onto 3 MM paper, dried and autoradiographed with Kodak X-OMAT AR ®lms for 3 to 4 h at room temperature. The autoradiographs were then developed and examined for evidence of LOH. Cases were considered to be informative when heterozygosity was detected in normal tissue samples. LOH was de®ned as a reduction of 50% or more in the band intensity of one of the tumor sample alleles compared to the normal tissue control. This reduction of intensity was determined either by visual examination by two dierent reviewers or following densitometric analysis. Repeat LOH analysis with a multiplex PCR routine for normalization was performed in those samples that appeared to show an increase in signal to con®rm loss of heterozygosity and not ampli®cation. Homozygous alleles in the normal tissue samples were labeled as uninformative.
Statistical analysis
A Chi-Square test was performed to compare LOH frequencies between histopathologic types, stages, and grades of the invasive cases. Statistical signi®cance was considered when P values were 50.05. 
